Evidence map›Paper›PMID 40118055›Full record

ArticleStem cell reports2025

The lung microvasculature promotes alveolar type 2 cell differentiation via secreted SPARCL1.

Paolo Panza, Hyun-Taek Kim, Till Lautenschläger, Janett Piesker, Stefan Günther, Yousef Alayoubi, Ondine Cleaver, Mario Looso, Didier Y R Stainier

Abstract read
In one paragraph

Article in Stem cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paolo PanzaDepartment of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; Department of Medicine V, Internal Medicine, Infectious Diseases and Infection Control, Justus-Liebig University Giessen, Giessen, Germany; Member of the German Center for Lung Research, DZL-UGMLC; Member of the Excellence Cluster Cardio-Pulmonary Institute, CPI. Electronic address: paolo.panza@mpi-bn.mpg.de.
Hyun-Taek KimDepartment of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Till LautenschlägerDepartment of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Janett PieskerScientific Service Group Microscopy, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Stefan GüntherDeep Sequencing Platform, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Yousef AlayoubiBioinformatics Core Unit, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Ondine CleaverUT Southwestern Medical Center, Dallas, TX, USA.
Mario LoosoBioinformatics Core Unit, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Didier Y R StainierDepartment of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; Member of the German Center for Lung Research, DZL-UGMLC; Member of the Excellence Cluster Cardio-Pulmonary Institute, CPI. Electronic address: didier.stainier@mpi-bn.mpg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung endothelial cells (ECs) and pericytes are closely juxtaposed with the respiratory epithelium before birth and thus may have instructive roles during development. To test this hypothesis, we screened EC-secreted proteins for their ability to alter cell differentiation in alveolar organoids. We identified secreted protein acidic and rich in cysteine-like protein 1 (SPARCL1) as an extracellular matrix molecule that can promote alveolar type 2 (AT2) cell differentiation in vitro. SPARCL1-treated organoids display lysozyme upregulation and a doubling in the number of AT2 cells at the expense of intermediate progenitors. SPARCL1 also induces the upregulation of nuclear factor κB (NF-κB) target genes, and suppression of NF-κB activation in lung organoids blocked SPARCL1 effects. NF-κB activation by lipopolysaccharide (LPS) was sufficient to induce AT2 cell differentiation; however, pharmacological inhibition of the pathway alone did not prevent it. These data support a role for SPARCL1 and NF-κB in alveolar cell differentiation and suggest a potential value in targeting this signaling axis to promote alveolar maturation and regeneration.

Indexed as

Alveolar Epithelial CellsCalcium-Binding ProteinsCell DifferentiationExtracellular Matrix ProteinsLungMicrovesselsAnimalsEndothelial CellsHumansLipopolysaccharidesMiceNF-kappa BOrganoidsSignal TransductionCalcium-Binding ProteinsExtracellular Matrix ProteinsLipopolysaccharidesNF-kappa BSPARCL1 protein, humanalveolar type 2 cellscell differentiationendothelial cellsextracellular matrixlung alveologenesislung developmentlung organoidspericytesSPARCL1vascular-epithelial crosstalk

Identifiers

PMID40118055
PMCPMC12069885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.